The general focus of my projects is on biomarkers in GBS.

In these projects, we aim to describe the (longitudinal) occurrence of promising biomarkers in relation to the clinical phenotype of patients with GBS. Markers that I work with include anti-ganglioside antibodies, soluble interleukin-2 receptor, neurofilament light chain, preceding infection serology, and single nucleotide polymorphisms (in genome-wide association studies).

With the results of these projects, we hope to improve care and treatment for patients with GBS through aiming to improve diagnostics, prognostics, and treatment strategies for these patients.